Włodzimierz Samborski

Włodzimierz Samborski

Auto-generated profile, based on publicly available information

Włodzimierz Samborski

Department of Rheumatology and Rehabilitation, Poznan University of Medical Sciences, Fredry 10, 61-701 Poznan, Poland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MZMichał Ziarko
Michał Ziarko
KSKatarzyna Siemiątkowska
Katarzyna Siemiątkowska
MSMichal Marcin Sienski
Michal Marcin Sienski
WSWłodzimierz Samborski
Włodzimierz Samborski
JSJoanna Samborska
Joanna Samborska
EMEwa Mojs
Ewa Mojs
Introduction. Rheumatoid arthritis (RA) is a long-term disorder significantly impairing the somatic, emotional, and psychological functioning of its sufferers. Previous research has shown that affected individuals are characterized by an increased level of anxiety and depression. Currently, there are two main treatment schemes for RA; the first uses anti-inflammatory drugs, and the second utilizes biologic agents. This begs the question whether sufferers differ in intensities of pain, anxiety, and depression depending on the type of treatment and what the determinants of these affective states in patients treated using different methods are. Methods. The study comprised 85 patients affected by RA (including 57 receiving biologically inactive medication). Research participants filled out a set of questionnaires measuring levels of anxiety and depression, intensity of experienced pain, strategies of coping with pain, and ego resiliency. Results. The collected data was analyzed through intergroup comparisons, calculating simple correlation coefficients, developing and solving regression equations. The results imply that the choice of treatment differentiates the intensity of pain experienced by patients. Those receiving biologic agents reported lower levels of pain compared to those taking anti-inflammatory medication. It has also been noted that there are distinct configurations of conditions conducive to anxiety and depression in both anti-inflammatory and biologic agent groups. Discussion. The observed constellation of dependencies between variables indicates that the choice of treatment scheme differentiates pain levels. This confirms the assumption that pain intensity, coping strategies, and ego resiliency depend on the severity of anxiety and depression.

27 September 2019 in Medical Principles and Practice
Verified
Journal Article
Open access
PDF file
MZMichał Ziarko
Michał Ziarko
EMEwa Mojs
Ewa Mojs
DSDorota Sikorska
Dorota Sikorska
WSWłodzimierz Samborski
Włodzimierz Samborski
Objective: Ego-resiliency is attributed the status of a “meta resource” that is responsible for a flexible selection of coping strategies depending on the requirements of a specific difficult situation. A considerably burdensome critical life event is the development of a chronic illness such as rheumatoid arthritis (RA). Apart from coping with the symptoms, a fundamental task confronting patients is maintaining their quality of life. This raises the question of whether ego-resiliency serves as a mediator between coping strategies and quality of life. Materials and Methods: 210 RA patients were invited to participate in this study. They were requested to complete a questionnaire that included the Satisfaction with Life scale, the stress coping inventory Mini-COPE, and the Ego-Resiliency scale. The collected data were analyzed by a simple mediation procedure and estimation of simple correlation coefficients. Results: The analysis demonstrated that ego-resiliency (r = 0.46; p < 0.001) and emotion-focused coping (r = 0.39; p < 0.001) determined life satisfaction. Additionally, ego-resiliency mediated the relation between emotion-oriented coping strategies and life satisfaction. Partial mediation was observed (a = 0.45**; b = 0.36**; c = 0.39**; c’ =0.22**; R2 = 0.24; F = 35.65; p < 0.001). Conclusion: Our observations partly support the assumption about a controlling role of ego-resiliency in the process of selecting coping strategies according to demands of situations.

11 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BBBogdan Batko
Bogdan Batko
EKEugene Joseph Kucharz
Eugene Joseph Kucharz
MSMarcin Stajszczyk
Marcin Stajszczyk
MBMAREK BRZOSKO
MAREK BRZOSKO
WSWłodzimierz Samborski
Włodzimierz Samborski
ZZZbigniew Zuber
Zbigniew Zuber
Introduction: Real-world data indicate disparities in biologic access across Europe. Objectives: To describe the national structure of PsA care in Poland, with a particular focus on the population of inadequate responders (IRs) and difficulties associated with biologic therapy access. Methods: A pool of rheumatologic and dermatologic care centers was created based on National Health Fund contract lists (n = 841), from which 29 rheumatologic and 10 dermatologic centers were sampled randomly and successfully met the inclusion criterium. Additionally, 33 tertiary care centers were recruited. For successful center recruitment, one provider had to recruit at least one patient that met the criteria for one of the four pre-defined clinical subgroups, in which all patients had to have active PsA and IR status to at least 2 conventional synthetic disease-modifying drugs (csDMARDs). Self-assessment questionnaires were distributed among physicians and their patients. Results: Barriers to biologic DMARD (bDMARD) treatment are complex and include stringency of reimbursement criteria, health care system, logistic/organizational, and personal choice factors. For patients who are currently bDMARD users, the median waiting time from the visit, at which the reimbursement procedure was initiated, to the first day of bDMARD admission was 9 weeks (range 2–212; 32% < 4 weeks, 29% 5–12 weeks, 26% 13–28 weeks, 13% with >28 weeks delay). Out of all inadequate responder groups, bDMARD users are the only group with “good” therapeutic situation and satisfaction with therapy. Patient satisfaction with therapy is not always concordant with physician assessment of therapeutic status. Conclusions: Despite the fact that over a decade has passed since the introduction of biologic agents, in medium welfare countries such as Poland, considerable healthcare system barriers to biologic access are present. Out of different IR populations, patient satisfaction with treatment is often discordant with physician assessment of disease status.

1 December 2019 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
AZAgnieszka Zuszek
Agnieszka Zuszek
JBJoanna Monika Borek
Joanna Monika Borek
Roksana MalakRoksana Malak
Roksana Malak
WSWłodzimierz Samborski
Włodzimierz Samborski
Introduction: There are many factors that affect temporomandibular joint dysfunction. These may include, among others: structural and postural disorders, bruxism, and occlusive abnormalities. In addition, an important aspect are psychological factors that, as a result of stress, can affect temporomandibular joint disorders through hyperactivity of the muscles, followed by biomechanical changes and related pain. These factors can lead to the production of neurotransmitters that disturb the balance of serotonin and catecholamines. Aim: Literature review to determine the relationship between temporomandibular joint disorders and psychological disorders in pediatric patients Material and methods: Based on the Research Gate, PubMed and Google Schoolar databases, a review of scientific papers was performed using the keywords: (temporomandibular joint), (stress, bruxism, mental disorders). Articles from the last 5 years have been analyzed. Results: Higher levels of anxiety are observed in patients with temporomandibular joint disorders. There is also a higher incidence of depression and chronic stress. Conclusions: Available literature shows the relationships between dysfunctions within the temporomandibular joint and mental disorders of the patient. However, research in this area should continue to show more detailed information regarding both the general relationship between the abovementioned aspects and the relationship between individual temporomandibular joint disorders and psychological aspects.

9 August 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
EMEwa Mojs
Ewa Mojs
MBMarek Brzosko
Marek Brzosko
WSWlodzimierz Samborski
Wlodzimierz Samborski

30 November 2020 in Aktualności Neurologiczne
Verified
Journal Article
Open access
MSMałgorzata Stachoń
Małgorzata Stachoń
MSMilena Sierocka
Milena Sierocka
PPPiotr Poniewierski
Piotr Poniewierski
Anna KostiukowAnna Kostiukow
Anna Kostiukow
WSWłodzimierz Samborski
Włodzimierz Samborski
Introduction: Isolation of two compounds, tetrahydrocannabinol (THC) and cannabidiol (CBD), contributed to an increased interest in the use of marijuana for medicinal purposes. It was then that research on the effects of marijuana on the course of different diseases began. Aim: The aim of this paper was to analyse the use of cannabinoids in the treatment of children with autism spectrum disorder. Results: There are different methods for cannabinoid administration. Researchers use various preparations with doses ranging between 0.04 mg to 900 mg. Preliminary studies are conducted on animal models, usually in genetically modified mice. Cannabinoids have been found to have a positive effect on social and emotional behaviours of children, as well as to show anxiolytic and antipsychotic effects. Cannabidiol plays an important role in the secretion of vasopressin and oxytocin. Some patients experience adverse effects. Antidepressant and anticonvulsant effects have been observed in patients with neurological and mental disorders. Conclusions: Cannabinoid therapy is not the standard of care in children with autism spectrum disorders, and the doses used vary significantly. There is evidence for the positive effects of cannabinoids in patients with comorbidities. It is possible that cannabinoids have an anxiolytic effect and allow for a reduced use of antipsychotics in the analysed group of patients. Antidepressant and anticonvulsant effects have also been observed. Furthermore, it was shown that CBDs administered in mice with Dravet syndrome improve social behaviour, dysfunction of which is one of the central symptoms of autism spectrum disorder.